Viewing Study NCT05731492


Ignite Creation Date: 2025-12-24 @ 3:52 PM
Ignite Modification Date: 2025-12-27 @ 8:30 AM
Study NCT ID: NCT05731492
Status: WITHDRAWN
Last Update Posted: 2025-03-30
First Post: 2023-02-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Macitentan in Children Below 2 Years of Age
Sponsor: Actelion
Organization:

Study Overview

Official Title: A Multicenter, Open-label, Single-arm Study to Assess the Pharmacokinetics and Safety of Macitentan in Children Aged 1 Month to <2 Years With Pulmonary Arterial Hypertension
Status: WITHDRAWN
Status Verified Date: 2025-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Sponsor Decision
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to learn what happens to macitentan and its active metabolite (aprocitentan) in the body of children aged between 1 month and 2 years.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2022-002754-74 EUDRACT_NUMBER None View
67896062PAH1013 OTHER Actelion Pharmaceuticals Ltd View